270
Participants
Start Date
February 7, 2020
Primary Completion Date
November 29, 2024
Study Completion Date
November 29, 2024
Polatuzumab Vedotin
Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.
Rituximab
Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
Gemcitabine
Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
Oxaliplatin
Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
Memorial Sloan-Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center at Westchester, Harrison
Memorial Sloan Kettering Nassau, Uniondale
MSKCC @ Commack, Commack
Instituto Nacional de Cancerologia, Distrito Federal
Hospital Univ. 12 de Octubre, Madrid
CHU de Nîmes - Hôpital Carémeau, Nîmes
Cancer Specialists, Jacksonville
Memorial Cancer Institute at Memorial West, Pembroke Pines
Tampere University Hospital, Tampere
Hopital De Haut Leveque, Pessac
Istanbul Uni Istanbul Medical Faculty, Istanbul
Istanbul University Cerrahpasa Medical Faculty, Istanbul
Amerikan HAstanesi Onkoloji Birimi Te?vikiye, Ni?anta??
Chungnam National University Hospital, Daejeon
Hospital Clinico Universitario de Salamanca, Salamanca
Hopital Bretonneau, Tours
Hospital Universitario de Canarias, San Cristóbal de La Laguna
Azienda Ospedaliero-Universitaria Policlinico di Modena Ematologia, Modena
Kocaeli Universitesi Tip Fakultesi, Kocaeli
Hospital Universitario Dr. Peset, Valencia
IHA Hematology Oncology Consultants - Ann Arbor, Ann Arbor
Pusan National University Hospital, Busan
Gyeongsang National University Hospital, Gyeongsangnam-do
Sakarya Universitesi Egitim ve Arastirma Hastanesi, Adapazari/Sakarya
USL 4 di Prato - Nuovo Ospeale di Prato, Prato
ICANS, Strasbourg
Uni Degli Studi Di Bari, Policlinico, Bari
Centre Henri Becquerel, Rouen
Universitätsklinikum Ulm, Ulm
Oulu University Hospital, Oulu
Hopital Henri Mondor, Créteil
All India Institute of Medical Sciences ,Institute Rotary Cancer Hospital, New Delhi
Institute of Hematology and Hospital of Blood Disease, Tianjin
The 1st Affiliated Hospital of Nanchang Unversity, Nanchang
Tata Memorial Hospital, Mumbai
Hu Nan Provincial Cancer Hospital, Changsha
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou
Guangxi Cancer Hospital of Guangxi Medical University, Nanning
West China Hospital - Sichuan University, Chengdu
Tata Medical Center, Kolkata
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an
Liga Norte Riograndense Contra O Câncer, Natal
MSKCC at Basking Ridge, Basking Ridge
Memorial Sloan Kettering - Monmouth, Middletown
Memorial Sloan Kettering Cancer Center at Bergen, Montvale
Hospital Sao Rafael - HSR, Salvador
Hospital das Clinicas - UFRGS, Porto Alegre
Hospital das Clinicas - FMUSP, São Paulo
London Health Sciences Centre, London
Niagara Health Systems - St. Catherines General Site, St. Catharines
McGill University Health Centre - Glen Site, Montreal
Centre hospitalier regional de Trois-Rivieres, Trois-Rivières
Laiko General Hospital, Athens
Attiko Hospital, Athens
St James' Hospital, Dublin
Az. Osp. Uni Ria Policlinico Tor Vergata, Rome
Hospital de Especialidades Centro Medico Nacional La Raza, Mexico City
Health Pharma Professional Research, Mexico City
Severance Hospital, Yonsei University Health System, Seoul
Hospital Universitari Germans Trias i Pujol, Badalona
Abdurrahman Yurtarslan Onkoloji Training and Research Hospital, Ankara
Akdeniz Uni School of Medicine, Antalya
Beatson West of Scotland Cancer Centre, Glasgow
Kings College Hospital, London
Nottingham City Hospital, Nottingham
Hoffmann-La Roche
INDUSTRY